Rithim Biologics®, Inc.

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Founded in March, 2016, Rithim Biologics is a privately held, early stage startup company developing surgical tools and kits for delivering gene therapies to treat tachycardias (fast heart rates) in humans. Our initial efforts are targeting atrial fibrillation (AF) and more specifically those patients at risk for post-operative (cardiac) AF (POAF) combining KCNH2-G628 gene therapy development with proprietary instrumentation and kits for efficacious delivery in humans. Approximately 6-9 million in the US and 30+ million people in the world suffer from AF. An estimated 400,000 patients in the US undergo cardiac
surgeries annually and about 40% will develop POAF. Worldwide there are about 1.2 million cardiac surgeries performed per year with a like percentage developing POAF. The annual financial burden on US healthcare for POAF is an estimated $ 2.8 billion and AF overall in the US is $ 26 billion. Our near-term objective is to eliminate POAF.
Company Type:
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
DAAViS™ Catheter System
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Co-Founder, Director
Rithim Biologics®, Inc.